Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03827343
Other study ID # 999919044
Secondary ID 19-C-N044
Status Active, not recruiting
Phase
First received
Last updated
Start date January 23, 2019
Est. completion date December 31, 2025

Study information

Verified date May 9, 2024
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Immunotherapy is changing the landscape of cancer therapy. Particularly unique to immunotherapy is the toxicity profile, which differs from chemotherapy-based strategies and can be associated with inflammatory responses and/or autoimmune type reactions resulting from activation of the immune system. Referred to as immune related adverse events (irAEs), these adverse events may require systemic immunosuppression or have other consequences and present unique management challenges. Specific to CAR T-cell and other adoptive cell therapies is the constellation of symptoms referred to as cytokine release syndrome (CRS), which can range in severity from mild to severe, and can require both cytokine directed blockade and/or systemic immunosuppression to ameliorate the side effects. While side effects may be unique to each individual immunotherapy, and may also be patient specific, cumulative experience will help to inform toxicity profiles and improve management of side effects and overall outcomes. Given the number of immunotherapeutic approaches at the NCI, the primary goal of this protocol is to facilitate retrospective chart review of various immunotherapy trials at the NCI used in the treatment of cancer to comprehensively study toxicity profiles. This study will not involve the use of specimens or participant contact. All data that is needed has already been collected on the individual treatment protocols and is available in CRIS records or protocol specific databases. Data will only be collected from treatment protocols where the PI has given permission for use of the data on the trial the subject was enrolled on. This protocol will be amended to incorporate new research objectives and new protocols as necessary....


Description:

Immunotherapy is changing the landscape of cancer therapy. Particularly unique to immunotherapy is the toxicity profile, which differs from chemotherapy-based strategies and can be associated with inflammatory responses and/or autoimmune type reactions resulting from activation of the immune system. Referred to as immune related adverse events (irAEs), these adverse events may require systemic immunosuppression or have other consequences and present unique management challenges. Specific to CAR T-cell and other adoptive cell therapies is the constellation of symptoms referred to as cytokine release syndrome (CRS), which can range in severity from mild to severe, and can require both cytokine directed blockade and/or systemic immunosuppression to ameliorate the side effects. While side effects may be unique to each individual immunotherapy, and may also be patient specific, cumulative experience will help to inform toxicity profiles and improve management of side effects and overall outcomes. Given the number of immunotherapeutic approaches at the NCI, the primary goal of this protocol is to facilitate retrospective chart review of various immunotherapy trials at the NCI used in the treatment of cancer to comprehensively study toxicity profiles. This study will not involve the use of specimens or participant contact. All data that is needed has already been collected on the individual treatment protocols and is available in CRIS records or protocol specific databases. Data will only be collected from treatment protocols where the PI has given permission for use of the data on the trial the subject was enrolled on or from standard of care protocols. This protocol will be amended to incorporate new research objectives and new protocols as necessary.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 500
Est. completion date December 31, 2025
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 1 Month to 120 Years
Eligibility - Retrospective chart review of various immunotherapy trials at the NCI used in the treatment of cancer to comprehensively study toxicity profiles. This study will not involve the use of specimens or participant contact. All data that is needed has already been collected on the individual treatment protocols and is available in CRIS records or protocol specific databases.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States National Cancer Institute (NCI) Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To develop a retrospective study to allow for comparison of immunotherapy related toxicity profiles and risk factors across a set of protocols in the NCI. Summary of immunotherapy related toxicity profiles and risk factors across a set of protocols in the NCI. 2 years
Secondary Evaluate infectious complications and their risk factors in patients who receive CAR-T cell therapy for cancer Summary of infectious complications and their risk factors in patients who receive CAR-T cell therapy for cancer 2 years
Secondary Evaluate the incidence, risk factors for, and treatment of HLH/MAS in patients who receive CAR-T cell therapy Incidence and risk factors for, and treatment of HLH/MAS in patients who receive CAR-T cell therapy 2 years
Secondary Incidence and time to resolution Incidence of and time to resolution of grade 3 and 4 cytopenias post-CAR T-cell therapy in those who achieve a complete remission. 2 years
Secondary Overall and relapse free survival Summary of overall and relapse free survival and transplant associated toxicities for patients undergoing HSCT following CAR-T cell therapy 2 years
Secondary Incidence of end organ toxicities Incidence of grade 3 and 4 end organ toxicities experienced within the first 30 days of CAR T-cell therapy and includes associations between pre-CAR organ function as well as post-CAR response to such toxicities as well as validate the CAR-Comorbidity Index as predictive model of CRS severity 2 years
Secondary Evaluate response and toxicity profile of second CAR T-cell infusions Summary of factors associated with response to second CAR T-cell infusion 2 years
Secondary Evaluate impact of race/ethnicity and obesity on CAR T-cell outcomes Summary of response and toxicity profiles in patients based on race/ethnicity and also in those who are obese compared to those who are not. 2 years
Secondary Evaluate impact of cryopreservation on outcomes following CAR T-cell infusion Summary of cryopreservation and patients' outcomes following CAR T-cell infusion 2 years
Secondary Evaluate outcomes for patients with ALL and Down Syndrome following CAR T-cell therapy Summary of outcomes of patients with ALL and Down Syndrome who have received CAR T-cell therapy 2 years
Secondary Evaluate absolute lymphocyte count following lymphodepleting chemotherapy Summary of absolute lymphocyte count across lymphodepleting regimens 2 years
Secondary Evaluate relationship between clinical variable and apheresis and manufacturing products Summary of clinical variables and apheresis and manufacturing products 2 years
Secondary Evaluate incidence of hypertension, identify risk factors for development of hypertension, summarize medical management in CAR setting, and identify complications Summary of incidence of hypertension, risk factors, medical management and complications 2 years
Secondary Describe baseline demographics, prior treatment characteristics and outcomes based on patients who are referred to CAR T-cell program Summary of demographics, prior treatment and outcomes for patients referred to CAR T-cell program 2 years
Secondary Incidence of pre-infusion BCA and use of BCA as a prognostic marker for CAR T-cell associated toxicity and efficacy Incidence of BCA pre-infusion and use as a prognostic marker for CAR T-cell associated toxicity and efficacy 2 years
Secondary Presence and durability of CD72 expression in both B-ALL and normal B-ALL/hematogones Summary of CD72 expression in both B-ALL and normal B-ALL/hematogones and evaluate use as prognostic marker for CAR T-cell associated toxicity and efficacy 2 years
Secondary Evaluate interventions, documentation of care goals, and use of palliative care consultation or other symptom management Summary of interventions, documentation of care goals, and use of palliative care consultation or other symptom management for patients treated with CAR T-cell therapy 2 years
Secondary Evaluate long-term outcomes of survivors who received CAR T-cell therapy Summary of long-term outcomes of survivors who received CAR T-cell therapy 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT06405152 - Assessment of Macrophage Activation syndromE in STill's Disease
Not yet recruiting NCT03721809 - Characterization of the Inflammatory Profile of Patients With Macrophage Activation Syndrome Secondary to Bacterial Sepsis N/A
Active, not recruiting NCT02780583 - Treatment of Macrophage Activation Syndrome (MAS) With Anakinra Phase 1
Active, not recruiting NCT01966367 - CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation Phase 1/Phase 2
Enrolling by invitation NCT01095146 - New Candidate Criteria for Diagnosis of Macrophage Activation Syndrome N/A
Recruiting NCT06339177 - Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
Recruiting NCT02569463 - Low-dose IL-2 ( Interleukin-2) Treatment in Macrophage Activation Syndrome(MAS) Phase 1/Phase 2
Not yet recruiting NCT05137496 - Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome Phase 3
Recruiting NCT05611710 - Anakinra in Dengue With Hyperinflammation ( AnaDen ) Phase 2
Completed NCT03311854 - A Study to Investigate the Safety and Efficacy of Emapalumab, an Anti-IFN-gamma mAb in Patients With Systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD) Developing Macrophage Activation Syndrome/Secondary HLH (MAS/sHLH) Phase 2
Recruiting NCT05001737 - Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE Phase 3
Completed NCT03332225 - A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis Phase 2
Completed NCT04339712 - Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction Phase 2